The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan

被引:9
|
作者
Hayashi, H
Sugio, K
Matsumata, T
Adachi, E
Takenaka, K
Sugimachi, K
机构
[1] KYUSHU UNIV,FAC MED,DEPT SURG 2,HIGASHI KU,FUKUOKA 812,JAPAN
[2] KYUSHU UNIV,FAC MED,DEPT PATHOL 2,FUKUOKA 812,JAPAN
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To clarify the clinical significance of the mutation of p53 gene in hepatocellular carcinoma (HCC), 90 resected specimens from Japanese patients were assayed using a polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. p53 mutations were detected in 25 cases (27.8%) at exons 4, 5, 6, 7, and 8, and the most frequent region of the mutation was at exons 5 and 7. No statistically significant correlation was observed between the p53 mutations and the clinical features except for the preoperative alpha-fetoprotein (AFP) level (P < .05). According to the pathological features, prognostic factors, such as size of the tumor, vascular invasion, fibrous capsule infiltration, and intrahepatic metastasis, showed no relationship to the existence of the mutation. However, p53 mutations were significantly associated with the degree of differentiation of HCC; that is, the mutation was found in 19 cases of 53 poorly differentiated HCCs (35.9%) and 2 of 3 cases of anaplastic HCCs (66.7%). The presence of p53 mutations was associated with a shortened cancer-free survival (P < .001, by log rank test) and a shortened survival (P < .05). A multivariate analysis by the Cox regression analysis showed that the p53 mutations were an unfavorable prognostic factor related to recurrence (P < .005), which is especially significant within the first postoperative year, These results suggest that the mutations of p53 gene of HCC might be an independent prognostic predictor to help in the selection of candidates who should undergo more intensive postoperative treatment.
引用
收藏
页码:1702 / 1707
页数:6
相关论文
共 50 条
  • [1] Mutation of tumor suppressor gene p53 in hepatocellular carcinomas from Korea
    Park, YM
    Yoo, YD
    Paik, SY
    Kim, BS
    Tabor, E
    [J]. EXPERIMENTAL AND MOLECULAR MEDICINE, 1996, 28 (04): : 173 - 179
  • [2] P53 GENE IN HEPATOCELLULAR CARCINOMAS FROM AUSTRALIA
    VESEY, DA
    HAYWARD, NK
    COOKSLEY, WGE
    [J]. CANCER DETECTION AND PREVENTION, 1994, 18 (02): : 123 - 130
  • [3] Clinical significance of p53 codon 72 polymorphism in hepatocellular carcinomas
    Council, Leona N.
    Shanmugam, Chandrakumar
    Katkoori, Venkat R.
    Sthanam, Meenakshi
    Hanna, Alex
    Manne, Upender
    [J]. CANCER RESEARCH, 2012, 72
  • [4] THE P53 GENE IN HUMAN HEPATOCELLULAR CARCINOMAS
    TERRIS, B
    MARCIO, A
    TIOLLAIS, P
    DEJEAN, A
    [J]. JOURNAL OF HEPATOLOGY, 1993, 17 (03) : 422 - 422
  • [5] No predominance of codon 249 mutation of the p53 gene in Myanmar hepatocellular carcinomas
    Win, Ne
    [J]. MODERN PATHOLOGY, 2006, 19 : 143 - 143
  • [6] P53 GENE MUTATION SPECTRUM IN HEPATOCELLULAR CARCINOMAS IN HONG-KONG CHINESE
    NG, IOL
    CHUNG, LP
    TSANG, SWY
    LAM, CL
    LAI, ECS
    FAN, ST
    NG, M
    [J]. ONCOGENE, 1994, 9 (03) : 985 - 990
  • [7] An aflatoxin-related mutation at codon 249 in p53 gene in hepatocellular carcinomas from Brazil
    Nogueira, Jeronimo
    Alves, Venancio
    Souza, Marcelo
    Nita, Marcelo
    Ono-Nita, Suzane
    Scapulatempo, Cristovam
    Mello, Evandro
    Wakamatsu, Alda
    Carrilho, Flair
    [J]. MODERN PATHOLOGY, 2006, 19 : 135 - 136
  • [8] Analysis of N-ras gene mutation and p53 gene expression in human hepatocellular carcinomas
    Dan, LUO
    Liu, QF
    Gove, C
    Naomov, NV
    Su, JJ
    Williams, R
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 1998, 4 (02) : 97 - 99
  • [10] MUTATIONAL HOTSPOT IN THE P53 GENE IN HUMAN HEPATOCELLULAR CARCINOMAS
    HSU, IC
    METCALF, RA
    SUN, T
    WELSH, JA
    WANG, NJ
    HARRIS, CC
    [J]. NATURE, 1991, 350 (6317) : 427 - 428